393509-22-3

Basic information

• Product Name: 2-(7-Fluoro-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid
• Synonyms: 2-(7-Fluoro-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid;(+/-) 2-(7-fluoro-1,2,3-trihydrocyclopenta[2,3-b]indol-3-yl)acetic acid
• CAS NO: 393509-22-3
• Molecular Formula: C₁₃H₁₂FNO₂
• Molecular Weight: 233.2382832
• Mol File: 393509-22-3.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 464.7°C at 760 mmHg
• Flash Point: 234.8°C
• Appearance: /
• Density: 1.393g/cm³
• Vapor Pressure: 1.96E-09mmHg at 25°C
• Refractive Index: 1.657
• PKA: 4.60±0.10(Predicted)
• CAS DataBase Reference: 2-(7-Fluoro-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(7-Fluoro-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid(393509-22-3)
• EPA Substance Registry System: 2-(7-Fluoro-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid(393509-22-3)

Safety Data

• Hazardous Substances Data: 393509-22-3(Hazardous Substances Data)

Usage

Chemical class

Acetic acid derivatives

Molecular structure

Contains a fluorine atom and a cyclopenta[b]indol structure

Biological and pharmacological activities

Has potential activities, but specific functions and applications are still being studied

Research and development

Used in the research and development of pharmaceuticals

Unique structure

Suggests potential in drug discovery and medicinal chemistry

Further research

Needed to fully understand the properties and potential uses of the compound

InChI:InChI=1/C13H12FNO2/c14-8-2-4-11-10(6-8)9-3-1-7(5-12(16)17)13(9)15-11/h2,4,6-7,15H,1,3,5H2,(H,16,17)

Upstream product

• 20826-94-2 ethyl (2-oxocyclopentyl)acetate 
• 61272-76-2 4-fluoro-2-iodoaniline 
• 371-40-4 4-fluoroaniline 
• 1003-98-1 2-bromo-4-fluoroaniline 
• 571170-84-8 [2-(2-bromo-4-fluoro-phenylimino)-cyclopentyl]-acetic acid ethyl ester 
• 393509-21-2 ethyl (7-fluoro-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetate 

Downstream Products

• 393509-23-4 (5-bromo-7-fluoro-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid 
• 571170-77-9 laropiprant 
• 571170-92-8 [4-(4-chloro-benzyl)-7-fluoro-5-methanesulfonyl-1,2,3,4-tetrahydro-cyclopenta[b]indol-3-yl]-acetic acid methyl ester 
• 794535-36-7 [5-acetyl-4-(4-chloro-benzyl)-7-fluoro-1,2,3,4-tetrahydro-cyclopenta[b]indol-3-yl]-acetic acid 
• 936337-07-4 methyl [(3R)-4-(4-chlorobenzyl)-7-fluoro-5-acetyl-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetate 
• 393509-04-1 [5-bromo-4-(4-chlorobenzyl)-7-fluoro-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetic acid 
• 571170-89-3 [5-bromo-4-(4-chloro-benzyl)-7-fluoro-1,2,3,4-tetrahydro-cyclopenta[b]indol-3-yl]-acetic acid methyl ester 
• 393509-05-2 [(3R)-5-bromo-4-(4-chlorobenzyl)-7-fluoro-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetic acid 

Relevant articles and documents

An efficient enzyme-catalyzed kinetic resolution: Large-scale preparation of an enantiomerically pure indole-ethyl ester derivative, a key component for the synthesis of a prostaglandin D2 receptor antagonist, an anti-allergic rhinitis drug can

Three racemic esters including indole-ethyl ester 1 as well as its related derivatives 3 and 4 in Scheme 1, all synthetic intermediates for the preparation of chiral compound 5, were used as substrates to evaluate the catalytic potentials of a panel of co

Method of Treating Pathological Blushing

A method of treating pathological blushing is disclosed wherein the patient is administered a DP receptor antagonist. Compositions containing DP antagonists are also included.

METHOD OF TREATING ATHEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED CONDITIONS

A method of treating atherosclerosis, dyslipidemia and related conditions is disclosed wherein a compound of formula I: or a pharmaceutically acceptable salt or solvate thereof is administered to the patient in combination with a DP receptor antagonist. T